09 October 2023
09 October 2023
The deal closed after the companies settled a US Federal Trade Commission lawsuit in September 2023.
Mirati focuses on the discovery, design and delivery of treatments for cancer.
Diabetes researchers oppose the regulation of islet transplantation as a biologic, following the approval of CellTrans’ Lantidra.
TREAT California started collecting signatures for a 5 November ballot measure that aims to raise money for psychedelic therapy research.
Ocular Therapeutix has confirmed the launch of a trial into the use of an eye implant, dubbed OTX-TKI, aimed at treating wet age-related macular degeneration.
Emergex and Saudi Vaccine Industrial Company (VIC) will develop T cell-priming immune set-point candidates against infectious diseases.
Limmatech, a GSK spinoff focused on combatting antimicrobial resistance, had sought series A funding seven years after foundation.
The expansion at the St. Louis (Missouri) would include up to four bioreactors to accommodate the production of biologic therapies.
Join us on October 17th, as Boris Baňas and Jan Storch discuss the challenges of sourcing certified cannabis for clinical trials and delve into CB21 Pharma's cannabis-derived product portfolio.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. KOLs remain hopeful that these companies will uncover a class of drugs that works effectively to slow or modify the disease course. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs.
Give your business an edge with our leading industry insights.
